Prof. Bridgewater is a leading Medical Oncologist Specialising in Gastrointestinal Cancers

Prof. Bridgewater is a distinguished medical oncologist with a specialisation in gastrointestinal cancers. He is currently affiliated with the Middlesex, Mount Vernon, and Royal Marsden Hospitals. After qualifying in medicine and surgery in 1986, he pursued a specialisation in medical oncology at these prestigious institutions. In 1999, he took on a senior lecturer position in medical oncology at University College London (UCL) and University College London Hospitals (UCLH).

Prof. Bridgewater's areas of expertise include upper gastrointestinal malignancies, with a particular focus on clinical and scientific research in gastrointestinal cancer. He leads the National Cancer Research Institute (NCRI) Study Group for upper gastrointestinal malignancy and the Genomics England Upper Gastrointestinal Workstream. His contributions to landmark studies over the past 20 years have significantly influenced the international standard of care for patients with gastrointestinal cancer.

A pioneer in personalised oncology treatment, Prof. Bridgewater's research has been instrumental in the development of novel therapies targeting faulty genes in cancers. His collaboration with AMMF, the cholangiocarcinoma charity, highlights his commitment to advancing personalised therapy for cancer patients. Through partnerships with the North Thames Genomic Laboratory Hub at the Royal Marsden and the HCA Genomic laboratories, he has successfully delivered personalised cancer treatments using targeted therapies, both bespoke and as part of clinical trials.

Prof. Bridgewater's clinical interests include chemotherapy, biliary cancer, bowel cancer, cancer of unknown primary, gastrointestinal cancers, and liver cancer. His research interests are centred around clinical trials offering novel and potentially more effective therapies to patients. He also engages in multiple laboratory-based collaborations with colleagues nationally and internationally, aiming to understand why treatments work and to design more effective strategies.

In addition to his clinical and research roles, Prof. Bridgewater has served on several national and international committees, including the Clinical Trials Advisory and Awards Committee (CTAAC), the National Institute for Health and Care Excellence (NICE) committee, the American Society of Clinical Oncology (ASCO) faculty, the National Institute of Health and Medical Research (INSERM) in France, and the French National Cancer Institute (INCa). His involvement in these committees ensures he remains at the forefront of the constantly advancing field of cancer research.

Prof. Bridgewater's dedication to improving patient outcomes through personalised treatment and innovative research makes him a leading figure in the field of medical oncology.